Session: MON 290-291-Endocrine Nursing
Poster Board MON-290
Methods: The SEISMIC Trial was a multicenter 24-week open label study of 50 patients (PTS) with persistent or recurring CS.3 Of the 50 PTS who completed the SEISMIC Trial, 30 PTS continued in the long term extension study following a 6 week medication washout period. Santos and Webb, et al, developed a 12-item CushingsQoL (CQoL) instrument designed and validated specifically to assess QoL in patients suffering from endogenous CS. 4,5 Twenty-three of 30 subjects consented to the CQoL at the 3 months study visit following extension study entry. The survey was administered twice via a single 20-minute phone interview conducted by an independent endocrine nurse practitioner. The survey compared item scores before SEISMIC study and during the most recent 4 week period on study drug.
Results: Scoring was calculated as % change over baseline. Domain scores were assessed on a 1-5 point ordinal scale, with higher scores representing improved QoL. Total composite score (n=23) improved by 52% compared to baseline and was highly Statistically Significant (SS) (p<0.001). SS % improvements were seen in the following domains: 86% bruising(p= 0.037), 74% socialization( p<0.001), 73% physical appearance(p<0.001), 59% sleep(p=0.001), 54% mood swings(p=0.005), 52% wound healing(p= 0.002), 50% desire for leisure activities(p<0.001), 45% illness impact on activities of daily living(p= 0.027), 45% worries about future health(p= 0.027), 44% pain(p= 0.037) and 44% confidence(p= 0.003).
Conclusion: PTS completing the disease-specific CQoL survey demonstrated significant improvement in overall composite and multiple domain scores of the CQoL. Chronic treatment of CS with mifepristone has shown improved measures in QoL.
Disclosure: SH: Employee, Corcept. Nothing to Disclose: DTA, PSV
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters